CIK 0001662774
- Non-accelerated filer
- Smaller reporting company
IRulya Therapeutics Inc.
Sign in to watch- Ticker
- IRLA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 901024039
- Phone
- +1 203-208-8994
- Business address
- 101 COLLEGE STREET, SUITE 210, NEW HAVEN, CT, 06510
- Former names
- Quince Therapeutics, Inc., Cortexyme, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-02-01 | Lynch Casey Chief Executive Officer | Sale | −371 | $39.23 | $15K | 1,078,774 |
| 2020-12-14 | Holsinger Leslie Executive Vice President | Option exercise | +40,000 | $0.27 | $11K | 43,500 |
| 2020-12-14 | Holsinger Leslie Executive Vice President | Sale | −1,700 | $28.80 | $49K | 41,800 |
| 2020-12-14 | Holsinger Leslie Executive Vice President | Sale | −14,275 | $30.15 | $430K | 27,525 |
| 2020-12-14 | Holsinger Leslie Executive Vice President | Sale | −13,200 | $30.91 | $408K | 14,325 |
| 2020-12-14 | Holsinger Leslie Executive Vice President | Sale | −9,525 | $31.79 | $303K | 1,800 |
| 2020-12-14 | Holsinger Leslie Executive Vice President | Sale | −400 | $32.59 | $13K | 4,400 |
| 2020-12-14 | Holsinger Leslie Executive Vice President | Sale | −900 | $32.59 | $29K | 3,500 |
| 2020-12-14 | Holsinger Leslie Executive Vice President | Option exercise · Stock Option (Right to Buy) | −40,000 | 66,794 | ||
| 2020-12-11 | Holsinger Leslie Executive Vice President | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2020-12-11 | Holsinger Leslie Executive Vice President | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2020-12-11 | Lynch Casey Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +175,000 | 175,000 | ||
| 2020-12-11 | Lynch Casey Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +175,000 | 175,000 | ||
| 2020-12-11 | Detke Michael J. Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2020-12-11 | Detke Michael J. Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2020-12-11 | Dominy Stephen S. Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2020-12-11 | Dominy Stephen S. Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2020-12-11 | LOWE CHRISTOPHER P. Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2020-12-11 | LOWE CHRISTOPHER P. Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2020-12-11 | McDowell Caryn Gordon Chief Legal & Adm. Officer | Grant or award · Stock Option (Right to Buy) | +75,000 | 75,000 |
Page 13 of 18 · 350 trades